Ad5.F35-GUCY2C-PADRE (GUCY2C-directed adenoviral vaccine) drives dose-dependent T-cell immunity and signals improved 2-year RFS in resected CRC
- Trial ID
- NCT04111172 on ClinicalTrials.gov
- Cancer type
- Colorectal Cancer
- Published in
- DOUBLE ISSUE: New in Oncology - July 8, 2026
Ad5.F35-GUCY2C-PADRE is an off-the-shelf chimeric Ad5/35 vector vaccine targeting the intestinal tumor antigen GUCY2C and incorporating PADRE to enhance CD4+ help, designed to bypass pre-existing anti-Ad5 neutralizing antibodies. In this open-label Phase 2A dose-finding study (NCT04111172) in resected high-risk GI adenocarcinomas with no evidence of disease post-adjuvant therapy (46 evaluable; CRC n=29; includes oligometastatic stage IV CRC n=8), three IM vaccinations q4w were given at 1×10^11, 1×10^12, or 5×10^12 viral particles; GUCY2C-specific ELISpot responses at 4 weeks post–dose 1 rose with dose (33%→94%→100% responders; p<0.0001) with higher-dose responses largely independent of baseline NAb status. Safety was benign (no DLTs, no TRSAEs; mostly grade 1–2 flu-like AEs), and among stage II–III CRC (excluding stage IV), recurrence rates at ~2 years numerically improved with dose (50% [4/8] at 1×10^11 vs 17% [1/6] at 1×10^12 vs 0% [0/7] at 5×10^12; p=0.051) with “median RFS not reached” at the two higher doses; immune responders also had significantly better RFS than non-responders (p<0.05). Versus current post-resection standard (surveillance after completion of adjuvant fluoropyrimidine/oxaliplatin where appropriate), this looks directionally better than the typical ~75% 3-year DFS seen in large Stage III adjuvant datasets—though this trial is small, noncomparative, and enriched for immunologic endpoints.
Take home
If this immune-response/RFS association holds up in a larger randomized setting, a well-tolerated, NAb-agnostic GUCY2C vaccine could become a true “maintenance-like” recurrence-prevention strategy after curative-intent CRC therapy—where today’s SOC is essentially “finish chemo, then watch,” and the bar is meaningful DFS gains without chronic toxicity.
Source: Read the original publication
More on NCT04111172
-
Trial result · Aug 13, 2026
Ad5.F35-GUCY2C-PADRE (adenoviral vaccine swapping Ad35 fiber) drives CD8+ immunity and fewer CRC recurrences -
Trial result · Jun 25, 2026
Ad5.F35-GUCY2C-PADRE (GUCY2C-directed adenoviral vaccine) drives dose-dependent T-cell immunity and signals improved 2-year RFS in resected CRC
More in colorectal cancer
-
New trial · Oct 15, 2026 · NCT07750158
Phase 3 STELLAR-316 tests zanzalintinib with or without pembrolizumab for ctDNA-positive, scan-negative colorectal cancer -
New trial · Oct 15, 2026 · NCT07842965
Phase 1/1b CHAMP adds CCR5 blockade with leronlimab to surgery, hepatic arterial floxuridine, and systemic therapy for colorectal liver metastases -
New trial · Oct 15, 2026 · NCT07551596
Phase 2 COMBAT tests botensilimab plus balstilimab for ctDNA-positive molecular residual disease in MSS colorectal cancer -
New trial · Oct 8, 2026 · NCT07811193
Phase 2 VVD-133214 WRN helicase covalent inhibitor + pembrolizumab (PD-1 antibody) in MSI/dMMR CRC -
New trial · Oct 8, 2026 · NCT07808151
Phase 2 porustobart CTLA-4 antibody + pembrolizumab PD-1 antibody in resectable MSS colon cancer
